Deepbridge Capital — 2021 Investments
2 investments dated 2021 · listed companies and verified rows first · show all
Glucose Republic builds software that predicts an individual's postprandial glucose and digestive response to whole meals before eating, modeling food matrices, digestive kinetics, and circadian physiology rather than relying on retrospective calorie logging.
AI & Machine LearningDigital HealthHealthtech
Julian Shapley(Co-founder)Matt Brooks(Executive Chair)
Glyconics develops medical diagnostic devices using spectroscopy (light-with-matter technology) to support low-cost medical diagnosis and disease management for patients and healthcare practice.
Deep TechDigital HealthHealthtechMedical Devices
Andrew Round(Chief Executive Officer (ad interim))Dr. Päivi Maria Paldánius(Chief Medical Officer & Chief Operating Officer)Sebastien Cuvelier Mussalian(Chief Technology Officer)Dr. Phil Taday(Head of R&D)Paul Jesson(Chief Finance Officer)
Co-investorsAnglia Capital GroupBoundary Capital
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.